Patents Assigned to Triact Therapeutics, Inc.
-
Patent number: 11628144Abstract: Disclosed herein are pharmaceutical compositions, formulations, and dosage forms and their use in the treatment of a cancer. Also disclosed herein are methods of treating a cancer in a subject in need thereof.Type: GrantFiled: September 28, 2018Date of Patent: April 18, 2023Assignee: TRIACT THERAPEUTICS, INC.Inventors: Thomas F. White, Stephen M. Nava
-
Patent number: 11433075Abstract: Disclosed herein are methods and compounds for treating glioblastoma with iniparib. Also disclosed herein is a method of selecting subjects having a glioblastoma for treatment based on a biomarker panel.Type: GrantFiled: January 19, 2021Date of Patent: September 6, 2022Assignee: TRIACT THERAPEUTICS, INC.Inventor: Thomas F. White
-
Patent number: 11433074Abstract: Disclosed herein are methods and compounds for treating glioblastoma with iniparib. Also disclosed herein is a method of selecting subjects having a glioblastoma for treatment based on a biomarker panel.Type: GrantFiled: June 22, 2018Date of Patent: September 6, 2022Assignee: TRIACT THERAPEUTICS, INC.Inventor: Thomas F. White
-
Patent number: 9834575Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor metabolite. Catecholic butane metabolites can serve as dual kinase inhibitors for purposes of methods described herein.Type: GrantFiled: February 26, 2014Date of Patent: December 5, 2017Assignee: TRIACT THERAPEUTICS, INC.Inventors: Thomas F. White, Steven Smith
-
Patent number: 9381246Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Patients to be treated include those that have been treated with Tarceva or other therapeutic compounds and relapsed or are resistant to treatment. The compounds described herein may exhibit a synergistic effect when administered with another agent.Type: GrantFiled: September 9, 2014Date of Patent: July 5, 2016Assignee: Triact Therapeutics, Inc.Inventors: Thomas F. White, Dan Hoth
-
Publication number: 20140249099Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor metabolite. Catecholic butane metabolites can serve as dual kinase inhibitors for purposes of methods described herein.Type: ApplicationFiled: February 26, 2014Publication date: September 4, 2014Applicant: TriAct Therapeutics, Inc.Inventors: Thomas F. WHITE, Steven SMITH
-
Publication number: 20140235714Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: TriAct Therapeutics, Inc.Inventors: Thomas F. WHITE, Edward F. SCHNIPPER, Dan HOTH
-
Patent number: 8710104Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.Type: GrantFiled: November 6, 2009Date of Patent: April 29, 2014Assignee: Triact Therapeutics, Inc.Inventors: Thomas F. White, Edward F. Schnipper, Dan Hoth